



Investing to improve the human condition. **Food and Health**

Steve Rhodes
Chair and CEO

Todd Dollinger
Chair and CEO

Haim Brosh
CFO

December 2022



Legal disclaimer.

Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. ("Company") or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.

Who **we** are.

Trendlines is an Israel-based company that trades in Singapore on the SGX (42T) and the USA on the OTCQX (TRNLY).



We invest in agrifood and medtech innovation to improve the human condition.

15

years' investment
and company
building experience

58*

portfolio
companies

20

advanced-stage
companies

10

exits

* including venture fund and consolidated companies

9.7X return and 175% IRR on exits

Equity US\$94 million (30.06.22)

Leadership.



Todd Dollinger
Chair and CEO

Trendlines' Founder;
over 40 years' experience
developing innovative
products from
concept to exit



Steve Rhodes
Chair and CEO

Trendlines' Founder;
over 40 years' experience, deep
understanding of
investing and building
companies



Haim Brosh
CFO

20 years' managerial and
financial
experience in
public and private
companies



Nitza Kardish PhD
CEO
Trendlines Agrifood

Vast experience in
food and agriculture
technologies
alongside strong
business acumen



Barak Singer
CEO,
Trendlines Investments
Israel

Extensive investment
knowledge & experience
+ strong managerial and
business capabilities



Eric Loh
CEO
Trendlines Medical
Singapore

Over 30 years' experience establishing
companies and leading
their development



Kobby Greenberg
Acting CEO
Trendlines Innovation
Labs

Brings a wealth of
experience in the medical
device industry.

Strategic partnerships for growth.



Chairman Vincent Tchenguiz

- Librae Holdings is Trendlines' largest shareholder (26.5%)
- Trendfood has invested \$10M in the Trendlines Agrifood Fund
- Agriline has invested US\$30 million in 27 of Trendlines' portfolio companies



- Investor in Trendlines' IPO, holding 2.9%
- Investor and acquirer of Trendlines' portfolio companies
- Partner with Trendlines Innovation Labs
- Founding partner, Trendlines Medical Singapore



- Co-founded venture fund with Trendlines for innovative agrifood investing
- Established four portfolio companies and made follow-on investments in them
- Informed consultation on all things agrifood

A taste of our
portfolio.



Some portfolio stats.

58*

portfolio
companies

14

revenue-stage
companies

20

companies with
strategic
partnerships

8

consolidated
companies

26

agrifood

32

medtech

* including venture fund and consolidated companies

The natural food color revolution.


A broad-spectrum of healthy plant-based colors produced via fermentation technology, using baker's yeast as a biofactory. Phytolon's high-quality and cost-effective pigments offer value for consumers, the environment and food industry.

Achievements:

- Full POC: color production & application in food products
- Commercial agreement with DSM
- Successful pilots with industry leaders including Nestlé
- R&D collaboration agreement with Ginkgo Bioworks

Financial stage:


- Last investment round: US\$14.5 million



Plant-based colors produced via cost-effective and sustainable fermentation of yeast


 **Founded** 2018;
23 employees;
Yokne'am Illit, IL

 **Co-Founders:**
Halim Jubran, PhD, CEO;
Tal Zeltzer, PhD, CTO

 **IP** licensed from
Weizmann Institute of
Science

 **Funding** US\$20.1 million

 **Investors** (see below)



4 more agrifood frontrunners.

26 agrifood portfolio companies

FruitSpec.

Early-stage prediction of crop yields in orchards and vines

- Sales in the United States, South America, Israel and South Africa
- Strategic investors from China and South Africa




Technology platform for harvesting greenhouse tomatoes

- Partnership with Dutch horticulture technology supplier Ridder 
- First commercial sales in 2022
- Received investment from European Innovation Council



Artificial intelligence analytics employing drones for user-generated data acquisition for field crop management

- Strategic partners in Israel, North America, Latin America, Europe and Africa. 
- Acquired Terravion assets to bolster imagery capabilities.



Orally-administered disease prevention for shrimp and fish

- Strategic investors:



Needleless neurotoxin delivery for overactive bladder.



Ultrasound catheter used to deliver Xeomin® in the treatment of overactive bladder, a common bladder disorder.

Achievements:






- Successful first in human study
- Strategic collaboration agreement with Merz Therapeutics licensing Merz's botulinum neurotoxin A (Xeomin®) for needle-free use in urological procedures




Financial stage:

- Last investment round: US\$19 million



Ultrasound catheter delivers Xeomin® into the bladder wall painlessly and without needles.

-  **Founded** 2014
-  **CEO** Avner Geva
-  **IP** Filed PCT
-  **Funding** Raised US\$21 million
-  **Investors** (see below)



Lewis Pell –
Angel investor

4 more leading medtech companies.

32 medtech portfolio companies



- Meniscus repair system
- FDA and CE clearance
 - Launched initial commercial sales in U.S., Latin America, U.K.
 - Appointed leading surgeons to Scientific Advisory Board



- Removable stent following sinus surgery
- Began sales in US
 - FDA clearance




- Digital home dialysis
- FDA clearance in process
 - 2nd clinical trial underway
 - Raised US\$8.1 million




- Non-surgical, incision-free approach to treat pelvic organ prolapse
- FDA clearance
 - 17 patient FIH clinical study with 1 year follow up completed – March 2022


Let's look at the
numbers.



Portfolio value with cumulative exit proceeds.




Book value vs. exit value.



4X is the increase in value of our ten exits, compared to their pre-exit book value.

Investments raised by portfolio companies*



*Including venture fund and consolidated companies

H1 2022: Key Financial Metrics.

	30 June 2022	31 December 2021
Portfolio value:	US\$81.0 million	US\$83.0 million
Book value:	US\$94.2 million	US\$102.5 million
NAV per share:	US\$0.12	US\$0.13
Net (loss)/profit	US\$ (11.9 million)	US\$4.1 million

Building for
future **results.**



2022 achievements so far.

Selected raises



Completed to US\$19 million



US\$14.5million



US\$1.6 million



US\$2.85 million

Strategic collaborations



Regulatory



escala medical

FDA clearance



FDA
breakthrough
device
designation

Clinical & field trials



escala medical

liberDi



PrègnanTech
Your Pregnancy. Our Focus.





Creating & developing companies
to improve the human condition.

SGX: 42T
OTCQX: TRNLY

+972.72.260.7000
www.trendlines.com



December 2022

Steve Rhodes, Chair and CEO
steve@trendlines.com

Todd Dollinger, Chair and CEO
todd@trendlines.com

Haim Brosh, CFO
haim@trendlines.com

GENERAL ANNOUNCEMENT::TRENDLINES INVESTOR PRESENTATION DECEMBER 2022**Issuer & Securities**

Issuer/ Manager

THE TRENDLINES GROUP LTD.

Securities

THE TRENDLINES GROUP LTD. - IL0011328858 - 42T

Stapled Security

No**Announcement Details**

Announcement Title

General Announcement

Date & Time of Broadcast

21-Dec-2022 17:36:29

Status

New

Announcement Sub Title

Trendlines Investor Presentation December 2022

Announcement Reference

SG221221OTHRN6GV

Submitted By (Co./ Ind. Name)

Haim Brosh

Designation

Joint Company Secretary

Description (Please provide a detailed description of the event in the box below)

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the Sponsor). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the Exchange) and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document. The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.